hundr
million
peopl
worldwid
suffer
upper
respiratori
viral
infect
urvi
annual
caus
wide
rang
virus
gener
divid
influenza
noninfluenza
ill
latter
usual
refer
simpli
common
cold
common
human
viral
afflict
eccl
common
cold
flu
share
common
symptom
includ
sore
throat
cough
nasal
congest
rhinorrhea
gener
viral
transmiss
via
contamin
surfac
aerosol
viral
particl
fior
et
al
turner
turner
et
al
eccl
although
variabl
term
pathogenesi
epidemiolog
tempor
appear
manifest
similar
case
urvi
selflimit
caus
minor
ill
patient
fulli
recov
howev
seriou
ill
develop
especi
among
certain
highrisk
group
young
elderli
adult
underli
respiratori
condit
immunosuppress
patient
chidekel
et
al
ghosh
et
al
kim
hodinka
result
annual
estim
total
econom
burden
billion
usa
noninfluenza
infect
fendrick
et
al
billion
attribut
annual
influenza
epidem
molinari
et
al
viral
pathogen
primarili
respons
common
cold
picornavirida
mostli
rhinovirus
coronavirida
adenovirida
turner
turner
et
al
human
rhinoviru
hrv
infect
account
around
asthma
chronic
obstruct
pulmonari
diseas
copd
exacerb
occasion
lead
seriou
complic
pneumonia
tan
et
al
current
approv
vaccin
directact
antivir
exist
prevent
treatment
rhinoviru
coronaviru
adenoviru
etiolog
agent
common
cold
avail
medic
provid
symptomat
relief
nation
institut
allergi
infecti
diseas
regard
influenza
addit
season
influenza
vaccin
approv
antivir
treatment
eg
oseltamivir
although
notabl
limit
typic
urvi
viru
enter
nasal
epithelium
replic
rapidli
spread
throughout
upper
respiratori
system
within
h
viral
protein
viru
particl
appear
surfac
epitheli
cell
adapt
immun
system
begin
process
select
expand
tand
bcell
necessari
elimin
infect
epitheli
cell
block
reinfect
free
viru
via
neutral
antibodi
respect
innat
immun
respons
act
rapidli
firstlin
defenc
prevent
viral
invas
replic
protect
adapt
immun
system
occur
cellular
innat
immun
respons
pattern
recognit
receptor
prr
engag
detect
specif
viral
compon
viral
rna
dna
viral
replic
intermedi
case
urvi
caus
mostli
rna
virus
involv
doublestrand
rna
intermedi
key
prr
tolllik
receptor
two
riglik
helicas
retino
acidinduc
gene
rigi
melanoma
differentiationassoci
protein
pichlmair
et
al
activ
prr
precipit
cascad
signal
event
lead
pleiotrop
respons
inhibit
viral
replic
within
cell
thompson
et
al
signal
neighbour
cell
render
refractori
viral
invas
takeuchi
akira
enhanc
migrat
immun
system
cell
area
koyama
et
al
mogensen
slater
et
al
infect
clear
tand
bcell
provid
memori
infect
confer
immun
specif
viru
last
year
previous
nasal
powder
dri
powder
proprietari
formul
polyinosin
polycytidyl
acid
sodium
salt
poli
poli
c
appli
nasal
poli
c
effect
immunomodul
current
develop
panvir
prophylaxi
common
cold
influenza
ill
poli
c
wellestablish
synthet
doublestrand
rna
act
viral
genom
surrog
activ
antivir
respons
cellular
innat
immun
system
stimul
prr
caskey
et
al
mian
et
al
preclin
inhous
mous
influenza
lethal
challeng
studi
unpublish
earli
clinic
studi
singl
ascend
dose
unpublish
suggest
would
safe
effect
prophylaxi
urvi
thu
placebocontrol
studi
conduct
evalu
effect
healthi
volunt
challeng
either
studi
studi
studi
phase
ibii
doubleblind
placebocontrol
trial
examin
efficaci
safeti
toler
repeat
prophylact
nasal
dose
healthi
adult
subject
subsequ
inocul
studi
studi
two
viral
strain
select
model
sinc
known
effect
elicit
symptomat
cold
virus
circul
flu
season
repres
frequent
occur
strain
suitabl
use
healthi
volunt
challeng
studi
obtain
wildtyp
challeng
viru
retroscreen
virolog
ltd
obtain
wildtyp
influenza
challeng
viru
meridian
life
scienc
challeng
virus
manufactur
current
good
manufactur
practic
gmp
undergon
qualiti
test
manufactur
regard
appear
steril
infect
contamin
accord
predetermin
specif
studi
initi
independ
ethic
committe
approv
obtain
studi
nre
committe
london
citi
east
studi
north
east
newcastl
north
tynesid
research
ethic
committe
subject
provid
written
inform
consent
prior
particip
studi
conduct
specialis
quarantin
unit
uk
studi
juli
septemb
studi
septemb
march
studi
elig
subject
compris
healthi
male
femal
age
year
inclus
bodi
mass
index
bmi
kgm
inclus
bodi
weight
kg
studi
inclus
criteria
similar
studi
although
subject
year
elig
particip
subject
screen
absenc
antibodi
relev
challeng
viru
subject
exclud
signific
acut
chronic
uncontrol
medic
ill
condit
includ
histori
abnorm
pulmonari
function
associ
increas
risk
complic
respiratori
viral
ill
would
make
subject
unsuit
quarantin
challeng
studi
subject
nonsmok
nonatop
use
medic
studi
drug
prohibit
except
hormon
replac
therapi
hrt
contracept
therapi
entir
quarantin
phase
studi
studi
follow
format
screen
prophylaxisinocul
within
quarantin
environ
followup
elig
subject
random
random
number
gener
sponsor
correspond
blind
treatment
kit
assign
sequenti
ascend
order
assign
random
number
determin
whether
subject
given
either
dose
match
placebo
one
dose
h
one
dose
h
prior
nasal
inocul
tcid
either
studi
studi
regimen
chosen
base
result
initi
rhinoviru
challeng
studi
singl
dose
administ
h
preinocul
see
addit
file
studi
result
includ
addit
fig
addit
tabl
studi
nasal
administ
dose
mg
administr
per
nostril
use
dri
powder
applic
follow
inocul
tcid
administ
two
instil
per
nostril
altern
nostril
instil
subject
observ
specif
potenti
allerg
reaction
within
min
follow
h
subject
monitor
throughout
quarantin
period
subject
complet
modifi
jackson
questionnair
assess
symptom
point
scale
time
daili
day
daili
nasal
discharg
collect
regular
nose
throat
lavag
sampl
taken
patient
return
follow
day
studi
approach
studi
assess
total
symptom
score
durat
symptom
mucu
product
viral
shed
seroconvers
percentag
subject
studydefin
clinic
ill
quarantin
period
viral
shed
monitor
nasal
lavag
quantit
realtim
polymeras
chain
reaction
qrtpcr
mackay
et
al
safeti
assess
throughout
studi
incid
treatment
emerg
advers
event
teae
chang
baselin
routin
clinic
laboratori
paramet
vital
sign
physic
examin
electrocardiogram
ecg
respect
studi
sinc
earli
develop
exploratori
studi
formal
statist
calcul
sampl
size
conduct
number
subject
includ
per
cohort
deem
suffici
evalu
object
similarli
respect
studi
formal
sampl
size
calcul
perform
howev
sampl
size
consist
previou
challeng
studi
similar
design
conduct
unit
sampl
size
support
histor
placebo
data
previous
conduct
influenza
viru
studi
histor
data
show
withingroup
coeffici
variat
total
symptom
score
auc
rang
minimum
averag
assum
twosid
ttest
signific
level
power
order
detect
reduct
total
symptom
score
auc
placebo
evalu
subject
per
treatment
group
respect
requir
thu
number
subject
includ
deem
suffici
evalu
object
studi
endpoint
summar
use
descript
statist
comparison
group
made
total
symptom
score
use
wilcoxon
rank
sum
test
statist
signific
base
alpha
level
chang
viral
load
report
ci
clinic
ill
evalu
rel
risk
compar
group
use
fisher
exact
test
fortyfour
subject
enrol
studi
challeng
viru
enrol
studi
challeng
viru
subject
studi
receiv
viral
challeng
complet
studi
fig
studi
three
subject
withdrawn
prior
receiv
viral
challeng
subject
elev
laboratori
result
subject
withdrawn
due
nasal
bleed
subject
receiv
viral
challeng
complet
studi
fig
studi
subject
male
age
rang
year
bmi
rang
kgm
subject
white
studi
subject
male
age
rang
year
bmi
rang
kgm
subject
white
full
demograph
detail
provid
tabl
nasopharyng
swab
taken
subject
admiss
quarantin
unit
test
neg
respiratori
viru
screen
femal
subject
neg
pregnanc
test
studi
subject
report
clinic
symptom
placebo
arm
respect
lower
mean
overal
total
symptom
score
observ
group
compar
placebo
placebo
respect
differ
statist
signific
alpha
level
tabl
also
reduc
median
total
symptom
score
wilcoxon
rank
sum
test
p
median
durat
symptom
also
reduc
day
arm
compar
day
placebo
group
studi
subject
report
clinic
symptom
placebo
arm
respect
prophylaxi
result
significantli
lower
median
total
symptom
score
compar
placebo
p
wilcoxon
rank
sum
test
furthermor
compar
upper
quartil
subject
sever
symptom
score
median
symptom
score
placebo
respect
prophylaxi
demonstr
compar
lower
total
symptom
score
p
median
durat
symptom
day
arm
compar
day
placebo
group
mean
total
symptom
score
time
studi
shown
fig
studi
mean
mucu
product
g
group
compar
g
placebo
group
studi
mean
mucu
product
g
group
compar
g
placebo
group
studi
mean
area
viral
loadtim
curv
lower
group
compar
placebo
differ
group
ci
time
peak
viral
shed
also
delay
arm
day
compar
placebo
day
studi
mean
area
viral
loadtim
curv
lower
group
compar
placebo
time
peak
viral
shed
also
delay
arm
day
compar
placebo
day
studi
reduc
peak
viral
shed
subject
consid
clinic
ill
laboratoryconfirm
presenc
ie
posit
cell
cultur
assay
least
least
posit
detect
pcr
assay
day
day
discharg
seroconvers
clinic
symptom
ie
report
cold
symptom
runni
nose
stuffi
nose
sneez
sore
throat
score
point
diari
card
least
consecut
day
base
criteria
studi
subject
consid
clinic
ill
placebo
arm
respect
result
observ
rel
risk
clinic
ill
ci
differ
placebo
statist
signific
p
fisher
exact
test
studi
criteria
appli
clinic
ill
regardless
whether
subject
deem
febril
mani
subject
experienc
signific
temperatur
elev
consist
literatur
report
natur
occur
influenza
chughtai
et
al
applic
definit
yield
subject
consid
clinic
ill
placebo
arm
respect
p
fisher
exact
test
onetail
studi
seroconvers
observ
subject
placebo
group
seroconvers
rate
placebo
arm
also
compar
studi
patient
placebo
patient
death
seriou
advers
event
sae
advers
event
ae
consid
sever
intens
report
either
studi
subject
withdrew
studi
studi
three
subject
withdrawn
prior
receiv
viral
challeng
group
subject
report
nasal
bleed
anoth
subject
increas
crp
placebo
group
subject
increas
alt
ae
lead
withdraw
consid
mild
intens
studi
subject
treatment
group
report
least
one
ae
studi
subject
placebo
group
subject
group
report
ae
major
ae
consid
mild
intens
ae
consid
sever
frequent
observ
ae
subject
treatment
group
studi
shown
tabl
case
procedur
haemorrhag
seen
studi
thought
result
scrape
nasal
line
deliveri
devic
result
activ
pharmaceut
ingredi
report
nasal
irrit
tast
sensat
associ
administr
either
placebo
activ
either
studi
studi
consist
pattern
clinic
concern
safeti
laboratori
urinalysi
test
case
abnorm
note
judg
clinic
signific
pattern
find
physic
examin
vital
sign
ecg
suggest
advers
effect
end
quarantin
period
day
follow
overal
welltoler
viral
challeng
studi
poli
c
wellestablish
synthet
doublestrand
rna
act
viral
genom
surrog
activ
antivir
respons
cellular
innat
immun
system
stimul
prr
caskey
et
al
mian
et
al
potent
immunomodul
agent
whose
mechan
action
well
character
wong
et
al
upon
enter
cell
poli
c
activ
express
number
gene
product
render
host
cell
refractori
viral
replic
kumar
et
al
releas
cytokin
chemokin
act
paracrin
fashion
activ
antivir
respons
adjac
cell
recruit
cell
adapt
immun
system
area
kawai
akira
savan
prophylact
potenti
poli
c
demonstr
use
multipl
virus
cell
cultur
pan
et
al
anim
model
wong
et
al
clinic
trial
lee
et
al
howev
pharmaceut
use
formul
nasal
applic
unavail
nasal
powder
proprietari
formul
poli
poli
c
protect
rna
degrad
ubiquit
rnase
enhanc
retent
nose
uptak
nasal
epitheli
cell
demonstr
earli
inhous
anim
studi
appli
nasal
caviti
nasal
powder
adher
mucosa
allow
particl
pynocytos
nasal
epitheli
cell
activ
innat
immun
respons
high
molecular
weight
polym
remain
cell
enter
system
circul
devincenzo
et
al
within
cell
like
rna
rapidli
degrad
mononucleosid
immedi
recycl
via
cellular
nucleosid
pool
new
cellular
rna
molecul
de
clercq
nordlund
et
al
consequ
liver
burden
potenti
hepat
drugdrug
interact
primari
pharmacolog
effect
local
area
applic
final
synthet
noncod
nonrepl
rna
polym
risk
unintend
amplif
attenu
viru
possibl
protein
product
potenti
could
lead
sensit
upon
repeat
administr
taken
togeth
give
appropri
profil
use
topic
prophylact
agent
urvi
anticip
natur
support
toxicolog
initi
firstinhuman
safeti
studi
except
safe
profil
suitabl
prophylaxi
common
cold
base
preclin
result
initi
rhinoviru
challeng
studi
conduct
studi
ident
studi
outlin
paper
howev
singl
dose
administ
h
preinocul
total
symptom
score
margin
reduc
compar
placebo
full
detail
singl
dose
studi
provid
addit
file
includ
addit
fig
addit
tabl
base
report
literatur
stowel
et
al
booster
dose
propos
lead
studi
design
use
studi
report
manuscript
two
random
placebocontrol
studi
aim
assess
prophylact
effect
repeat
nasal
dose
healthi
volunt
challeng
either
studi
studi
result
studi
demonstr
strong
prophylact
effect
repeat
dose
healthi
subject
challeng
either
symptom
score
durat
symptom
mucu
product
viral
shed
reduc
find
signific
demonstr
effect
two
strain
respiratori
virus
differ
structur
ie
envelop
nonenvelop
virus
differ
type
rna
genom
replic
scheme
therefor
support
potenti
panvir
prophylaxi
agent
furthermor
percentag
volunt
studydefin
laboratori
confirm
ill
reduc
studi
studi
noteworthi
even
subject
sever
symptom
score
show
signific
compar
improv
treatment
p
seroconvers
rate
compar
suggest
use
would
prevent
gener
protect
longterm
memori
respons
specif
virus
final
welltoler
clinic
signific
ae
observ
either
studi
howev
import
acknowledg
limit
studi
sinc
small
sampl
size
approxim
subject
per
studi
also
conduct
highli
control
condit
ie
inocul
time
h
prophylaxi
larger
scale
studi
need
confirm
efficaci
safeti
real
world
set
prophylaxi
dose
h
prechalleng
prove
efficaci
two
entir
differ
viral
class
rhinoviru
influenzaa
viru
suggest
pleiotrop
effect
trigger
innat
immun
respons
benefici
mani
viral
pathogen
potenti
effect
prophylact
agent
upper
respiratori
viral
pathogen
although
studi
size
small
rhinoviru
influenza
challeng
model
sui
generi
would
appear
prophylaxi
effect
rhinoviru
influenza
whether
simpli
natur
innat
immun
respons
function
fact
rhinoviru
temperaturerestrict
viru
ie
limit
upper
airway
unlik
influenza
unclear
requir
investig
nevertheless
appear
topic
prophylaxi
potenti
provid
broad
coverag
impact
viral
infect
initi
upper
respiratori
system
specif
regard
influenza
season
vaccin
avail
potenti
augment
vaccin
protect
nasal
powder
innat
immun
system
stimul
provid
protect
variant
influenza
virus
may
includ
season
vaccin
also
rapid
onset
efficaci
compar
vaccin
within
h
dose
addit
expect
cellular
innat
immun
respons
remain
robust
age
zhao
et
al
suggest
use
elderli
could
augment
diminish
efficaci
season
influenza
vaccin
popul
weinberg
et
al
comparison
chemoprophylaxi
neuraminidas
inhibitor
appear
base
initi
challeng
studi
less
effect
howev
oseltamivir
zanamivir
limit
influenza
unlik
carri
toxic
issu
preclud
extend
season
use
direct
antivir
potenti
select
resist
variant
gubareva
et
al
although
larger
longterm
studi
yet
conduct
mechan
action
ie
activ
pleotrop
innat
immun
respons
make
unlik
select
simpl
resist
variant
influenza
upper
respiratori
viru
likewis
without
longerterm
trial
imposs
predict
toxic
issu
extend
administr
howev
potenti
sideeffect
would
undoubtedli
local
due
lack
system
exposur
final
remain
possibl
longterm
exposur
may
result
tachyphylaxi
due
local
downregul
innat
respons
nasal
line
becom
appar
longterm
studi
conclus
attenu
sever
durat
infect
reduc
number
individu
studydefin
laboratori
confirm
ill
common
cold
influenza
ill
without
compromis
seroconvers
safe
welltoler
support
evalu
potenti
panvir
prophylaxi
upper
respiratori
viral
infect
may
novel
strategi
improv
hrv
influenza
control
especi
highrisk
popul
elderli
underli
respiratori
condit
eg
asthma
copd
urvi
present
seriou
concern
ethic
approv
consent
particip
studi
initi
independ
ethic
committe
approv
obtain
studi
nre
committe
london
citi
east
studi
north
east
newcastl
north
tynesid
research
ethic
committe
subject
provid
written
inform
consent
prior
particip
applic
dataset
gener
andor
analys
current
studi
publicli
avail
sinc
inform
confidenti
proprietari
part
patent
file
howev
author
will
releas
appropri
inform
request
legitim
appropri
confidenti
agreement
place
develop
janssen
research
develop
develop
prep
biopharm
ltd
author
either
past
present
salari
employe
either
janssen
research
develop
prep
biopharm
ltd
bm
also
chief
scientif
offic
prep
biopharm
ltd
studi
fund
prep
biopharm
ltd
janssen
research
develop
also
design
studi
protocol
collect
data
conduct
analys
medic
write
support
provid
debbi
jordan
fund
prep
biopharm
ltd
